Patents Examined by Delia M. Ramirez
  • Patent number: 11981940
    Abstract: Compositions and methods comprising novel deaminase polypeptides for targeted editing of nucleic acids are provided. Compositions comprise deaminase polypeptides. Also provided are fusion proteins comprising a DNA-binding polypeptide and a deaminase of the invention. The fusion proteins include RNA-guided nucleases fused to deaminases, optionally in complex with guide RNAs. Compositions also include nucleic acid molecules encoding the deaminases or the fusion proteins. Vectors and host cells comprising the nucleic acid molecules encoding the deaminases or the fusion proteins are also provided.
    Type: Grant
    Filed: September 1, 2022
    Date of Patent: May 14, 2024
    Assignee: LifeEDIT Therapeutics, Inc.
    Inventors: Tyson D. Bowen, Alexandra Briner Crawley, Tedd D. Elich
  • Patent number: 11965200
    Abstract: The present invention relates to a recombinant microorganism imparted with increased ability to produce glutaric acid by further introducing a gene encoding a polypeptide having glutaric acid transporter activity into a microorganism having ability to produce glutaric acid, and to a method of preparing glutaric acid using the recombinant microorganism. According to the present invention, glutaric acid used for the preparation of various compounds such as polyamide, polyurethane, 1,5-pentanediol, and 5-hydroxyvaleric acid can be biosynthesized at high yield.
    Type: Grant
    Filed: December 13, 2021
    Date of Patent: April 23, 2024
    Inventors: Sang Yup Lee, Tae hee Han
  • Patent number: 11946092
    Abstract: A method for producing 2-keto-3-deoxygluconate (KDG) from 2-(acetylamino)-2-deoxy-D-gluconic acid (GlcNAc1A) by two enzymes; GlcNAc1A is converted to KDG by incubating GlcNAc1A with a deacetylase OngB at 25° C. for 4-12 h and then with a deaminase OngC at 25° C. for another 10-15 h; it constructs two engineered E. coli/pET22b-ongB (carrying the ongB gene) and E. coli/pET22b-ongC (carrying the ongC gene) strains to prepare recombinant proteins OngB and OngC, respectively; at the action of these two enzymes, OngB and OngC, GlcNAc1A is converted to KDG, which solves the bottleneck of GlcNAc1A utilization during the bioconversion of chitin; the KDG is an important metabolic intermediate to synthesize furan derivatives, herbicides, food additives and other industrially important chemical compounds, having wide industrial applications.
    Type: Grant
    Filed: October 31, 2022
    Date of Patent: April 2, 2024
    Inventors: Yuzhong Zhang, Pingyi Li, Wenxin Jiang, Xiulan Chen, Yishuo Zhang, Xiaoyan Song
  • Patent number: 11946084
    Abstract: Provided are a fusion protein comprising a Pab1 element and an eIF4G element and a preparation method therefor. The fusion protein can improve in-vitro translation efficiency. A constitutive or inducible promoter (for example, pKlPGK1) may also be inserted in front of eIF4G in the fusion protein for increasing in-vitro protein synthesis ability.
    Type: Grant
    Filed: December 13, 2017
    Date of Patent: April 2, 2024
    Inventors: Min Guo, Shuailong Liu, Xue Yu
  • Patent number: 11926655
    Abstract: The present invention provides a novel peptide that has an amino acid sequence represented by SEQ ID NO: 18, and binds to an active protease but does not bind to a pro-protease.
    Type: Grant
    Filed: July 17, 2018
    Date of Patent: March 12, 2024
    Assignee: Daiichi Sankyo Company, Limited
    Inventors: Hidenori Yano, Daisuke Nishimiya, Ryuji Hashimoto, Yoichi Niitsu
  • Patent number: 11913053
    Abstract: Provided is an application of trehalase in fermentative production. The trehalase has amino acid sequences shown in SEQ ID NO.6, SEQ ID NO.7, and SEQ ID NO.8. Provided are methods for producing and applying trehalase, particularly being applied in the production and fermentation of alcohol and an amino acid.
    Type: Grant
    Filed: September 17, 2019
    Date of Patent: February 27, 2024
    Assignee: Nanjing Bestzyme Bio-Engineering Co., Ltd.
    Inventors: Jie Lin, Hongxian Xu, Hui Peng
  • Patent number: 11898173
    Abstract: Disclosed are a recombinant acid-resistant yeast having improved lactic-acid-producing ability and a method of preparing lactic acid using the same. When producing lactic acid using the recombinant acid-resistant yeast according to the present invention, not only lactic-acid fermentation can be performed with lactic-acid-producing ability similar to that of bacterial fermentation using a remarkably smaller amount of a neutralizing agent than in the case of conventional bacterial fermentation, but also the production of ethanol and glycerol which are byproducts can be reduced. Thus, fermentation costs can be greatly reduced and the cost of subsequent purification processes can be reduced.
    Type: Grant
    Filed: June 21, 2021
    Date of Patent: February 13, 2024
    Assignee: SK Innovation Co., Ltd.
    Inventors: Jae Yeon Park, Tae Young Lee, Ki Sung Lee
  • Patent number: 11884941
    Abstract: Artificial lipoproteins bearing non-canonical post-translational modifications that are synthesized by leveraging substrate promiscuity of an acyltransferase. The non-canonical functionality of these lipoprotein results in a distinctive hysteretic assembly that is absent from the canonical lipoproteins and is used to prepare hybrid multiblock materials with precise and programmable patterns of amphiphilicity due to the unique assembly and function of the non-canonical post-translational modifications.
    Type: Grant
    Filed: November 18, 2021
    Date of Patent: January 30, 2024
    Inventor: Davoud Mozhdehi
  • Patent number: 11840712
    Abstract: The present disclosure provides engineered human extracellular DNASE proteins (e.g., variants of DNASE1 (D1), DNASE1-LIKE 1 (D1L1), DNASE1-LIKE 2 (D1L2), DNASE1-LIKE 3 Isoform 1 (D1L3), DNASE1-LIKE 3 Isoform 2 (D1L3-2), DNASE2A (D2A), and DNASE2B (D2B)) that are useful for treating conditions characterized by neutrophil extracellular trap (NET) accumulation and/or release. In accordance with the invention, the DNase variant has advantages for therapy and/or large-scale manufacturing.
    Type: Grant
    Filed: March 23, 2021
    Date of Patent: December 12, 2023
    Assignee: Neutrolis, Inc.
    Inventors: Tobias A. Fuchs, Abdul Hakkim R.
  • Patent number: 11814620
    Abstract: Provided herein are compositions, systems, and methods comprising effector proteins and uses thereof. These effector proteins are shown to be active with guide RNAs and may be characterized as CRISPR-associated (Cas) proteins. Various compositions, systems, and methods of the present disclosure leverage the activities of these effector proteins for the modification, detection, and engineering of nucleic acids.
    Type: Grant
    Filed: May 17, 2022
    Date of Patent: November 14, 2023
    Assignee: Mammoth Biosciences, Inc.
    Inventors: Benjamin Julius Rauch, Aaron DeLoughery, William Douglass Wright, David Paez-Espino, Clarissa Oriel Rhines, Lucas Benjamin Harrington, Wiputra Jaya Hartono
  • Patent number: 11788077
    Abstract: The present invention encompasses engineered nucleases which recognize and cleave a recognition sequence within a Hepatitis B virus (HBV) genome. The engineered meganucleases can exhibit at least one optimized characteristic, such as enhanced specificity and/or efficiency of indel formation, when compared to the first-generation meganuclease HBV 11-12x.26. Further, the invention encompasses pharmaceutical compositions comprising engineered meganuclease proteins, nucleic acids encoding engineered meganucleases, and the use of such compositions for treating HBV infections or hepatocellular carcinoma.
    Type: Grant
    Filed: September 20, 2021
    Date of Patent: October 17, 2023
    Assignee: Precision BioSciences, Inc.
    Inventors: James Jefferson Smith, Janel Lape, Victor Bartsevich, Hui Li
  • Patent number: 11781182
    Abstract: Presented herein are polymerase enzymes for improved incorporation of nucleotide analogues, in particular nucleotides which are modified at the 3? sugar hydroxyl, as well as methods and kits using the same.
    Type: Grant
    Filed: July 15, 2020
    Date of Patent: October 10, 2023
    Assignee: ILLUMINA, INC.
    Inventors: Erin Bomati, Molly He, Cheng-Yao Chen, Sergio Peisajovich
  • Patent number: 11773033
    Abstract: The present disclosure relates to consortia of bacteria strains and composition comprising one or more bacterial strains disclosed herein. These consortia of isolated bacteria cultures and compositions comprising said cultures, having greater activity than would be observed for the individual bacteria cultures and compositions. A composition of the disclosure may advantageously be used for enhancing the availability of soil phosphorus and other macronutrients and/or micronutrients to plants, and thereby enhancing their growth and yield.
    Type: Grant
    Filed: June 6, 2022
    Date of Patent: October 3, 2023
    Assignee: Colorado State University Research Foundation
    Inventors: Matthew D. Wallenstein, Colin W. Bell
  • Patent number: 11760985
    Abstract: The invention related to the field of genetic engineering tools, methods and techniques for gene or genome editing. Specifically, the invention concerns isolated polypeptides having nuclease activity, host cells and expression vectors comprising nucleic acids encoding said polypeptides as well as methods of cleaving and editing target nucleic acids in a sequence-specific matter. The poly peptides, nucleic acids, expression vectors, host cells and methods of the present invention have application in many fields of biotechnology, including, for example, synthetic biology and gene therapy.
    Type: Grant
    Filed: December 17, 2021
    Date of Patent: September 19, 2023
    Inventor: John Van Der Oost
  • Patent number: 11753630
    Abstract: The present disclosure encompasses engineered meganucleases that bind and cleave recognition sequences within a dystrophin gene. The present disclosure also encompasses methods of using such engineered meganucleases to make genetically modified cells. Further, the disclosure encompasses pharmaceutical compositions comprising engineered meganuclease proteins, or polynucleotides encoding engineered meganucleases of the disclosure, and the use of such compositions for the modification of a dystrophin gene in a subject, or for treatment of Duchenne Muscular Dystrophy.
    Type: Grant
    Filed: September 13, 2022
    Date of Patent: September 12, 2023
    Assignee: Precision BioSciences, Inc.
    Inventors: Gary Owens, Janel Lape, James Jefferson Smith, John Morris, Caitlin Turner, Whitney Lewis, Derek Jantz
  • Patent number: 11753662
    Abstract: A method of producing 3-oxoadipic acid from an aliphatic compound easily utilizable by a microorganism, such as a saccharide, by utilization of a metabolic pathway of the microorganism is disclosed.
    Type: Grant
    Filed: November 4, 2020
    Date of Patent: September 12, 2023
    Inventors: Kyohei Isobe, Kenji Kawamura, Masateru Ito, Katsushige Yamada
  • Patent number: 11725030
    Abstract: The present disclosure relates to methods for producing recombinant proteins, as well as compositions used in and produced by such methods. Specifically, the present disclosure relates to methods for producing high secreted yields of recombinant proteins, and the compositions provided herein include expression constructs, recombinant vectors, and recombinant host cells that comprise polynucleotide sequences encoding proteins operably linked to recombinant secretion signals that comprise the leader peptide of the ?-mating factor (?MF) of Saccharomyces cerevisiae and a non-?MF signal peptide.
    Type: Grant
    Filed: March 15, 2022
    Date of Patent: August 15, 2023
    Assignee: BOLT THREADS, INC.
    Inventors: Joshua Kittleson, Thomas Stevens, Rena Hill, Carlos Gustavo Pesce, David N. Breslauer, Daniel M. Widmaier
  • Patent number: 11702645
    Abstract: The present invention aims to provide a modified Cas9 protein with relaxed restriction on target sequence while maintaining binding ability to guide RNA, and use thereof. A protein containing the amino acid sequence of SEQ ID NO: 1 in which the 1335-position arginine is mutated into alanine (R1335A), isoleucine (R1335I), methionine (R1335M), threonine (R1335T) or valine (R1335V), the 1111-position leucine is mutated into arginine (L1111R), the 1135-position aspartic acid is mutated into valine (D1135V), the 1218-position glycine is mutated into arginine (G1218R), the 1219-position glutamic acid is mutated into phenylalanine (E1219F), the 1322-position alanine is mutated into arginine (A1322R), and the 1337-position threonine is mutated into arginine (T1337R), and the like.
    Type: Grant
    Filed: June 24, 2022
    Date of Patent: July 18, 2023
    Assignee: The University of Tokyo
    Inventors: Osamu Nureki, Hiroshi Nishimasu, Hisato Hirano
  • Patent number: 11702681
    Abstract: Disclosed is a mutant strain having the ability to produce polyhydroxybutyrate. The novel strain has a significantly high growth rate and an improved ability to produce PHB compared to existing PHB-producing cyanobacterial strains. Therefore, the novel strain is suitable for use in the production of PHB and the development of various products using PHB. In addition, the novel strain is useful as a photosynthetic strain for developing a PHB production process using industrial flue gas due to its ability to produce PHB from only CO2 without any additional organic carbon source. Also disclosed is a method for producing polyhydroxybutyrate using the mutant strain.
    Type: Grant
    Filed: December 29, 2021
    Date of Patent: July 18, 2023
    Assignee: Korea University Research and Business Foundation
    Inventors: Sang Jun Sim, Hyejin Roh, Jeong Seop Lee
  • Patent number: 11697831
    Abstract: Disclosed is the production by fermentation of poly D-lactic acid (PDLA) and poly L-lactic acid (PLLA). In particular, there is provided engineered (prokaryotic or eukaryotic) cells for the direct synthesis of PLLA polymers and engineered eukaryotic cells for the direct synthesis of PDLA polymers starting from a carbon source, including residual biomasses of the different production chains.
    Type: Grant
    Filed: July 31, 2019
    Date of Patent: July 11, 2023
    Inventors: Danilo Porro, Paola Branduardi, Stefano Bertacchi, Nadia Maria Berterame